Steve Harr, CEO of Sana Biotechnology, discusses the year ahead for Sana following the company’s recent positive clinical results from its type 1 diabetes study. More from Flagship @ JPM2025 here.
Related Companies
- Sana Biotechnology Founded: 2018
More from:
Human Health
2025 Company Chat: Jens Vogel, President & Chief Operating Officer of Mirai Bio
2025 CEO Chat: Lovisa Afzelius, Co-Founder & Founding CEO of Prologue Medicines
2025 CEO Chat: Margo Georgiadis, CEO of Montai
2025 CEO Chat: Stéphane Bancel, CEO of Moderna
Three Questions with Junaid Bajwa, Flagship Senior Partner, Head of UK, and Science Partner for Pioneering Intelligence
